Skip to main content
Zyvex Zyvex Pharmaceuticals
Photo 1 of 1 Click to zoom

Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.

Selective Androgen Receptor Modulators

Ostarine (MK 2866)

Enobosarm

Compound
Enobosarm
Brand
Ostarine
Manufacturer
Zyvex Pharmaceuticals
Presentation
100 tabs
Strength
25 mg/tab
Route
Oral
Storage
15–25 °C, protected from light, do not freeze

Batch analysis

Independent batch results for Ostarine (MK 2866) are not yet published. They will be added here once testing is complete.

Product information

About Ostarine (MK 2866)

25 mg per tablet · 100 tablets · Zyvex Pharmaceuticals

Ostarine (MK 2866) from Zyvex Pharmaceuticals contains enobosarm at 25 mg per tablet and comes in a pack of 100 tablets.

This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.

Basic Identification & Composition

Product Name & Active Ingredient

Ostarine (MK 2866) is the product name used by Zyvex Pharmaceuticals. The ingredient discussed in the following sections is enobosarm, classified as a selective androgen receptor modulator.

Qualitative & Quantitative Composition

Property Details
Product name Ostarine (MK 2866)
Manufacturer Zyvex Pharmaceuticals
Active ingredient Enobosarm
Strength 25 mg per tablet
Package 100 tablets
Drug class Selective androgen receptor modulator
Chemical formula C19H14F3N3O3
Dosage form and route Tablet; oral

Dosage Form

A solid tablet for oral administration. Each tablet provides a measured amount of active ingredient. Confirm suitability with a pharmacist before splitting or crushing; appearance and score lines alone do not establish accurate dose division.

Clinical Particulars

Ostarine (MK 2866) uses

Ostarine (MK 2866) from Zyvex Pharmaceuticals contains enobosarm. Enobosarm is a selective androgen receptor modulator investigated for muscle wasting, including cancer-related loss of lean tissue. It has also been investigated in other disease settings; results depend on the population and clinical endpoint.

People use enobosarm outside research in pursuit of lean mass, strength and muscle retention during dieting. Such motives do not demonstrate reliable functional benefit or improved wellbeing.

A phase II cancer trial studied oral doses of 1 or 3 mg once daily for up to 113 days. These are supervised research examples, not a common self-treatment protocol. A catalogue tablet strength and claims about physique use cannot establish equivalent exposure or outcomes.

Dosage and Administration

A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. Research dosing is protocol-specific and should not be converted into a bodybuilding or post-cycle schedule.

Contraindications

A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety.

Warnings and Precautions

Potential concerns include liver injury, changes in lipids and suppression of normal hormone production. The term "selective" does not mean that effects are limited to muscle. Seek assessment for jaundice, dark urine, persistent itching or severe fatigue.

Risks and Interactions

Drug & Food Interactions

Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe. Other androgens or compounds that affect the liver may add to clinical risk.

Pregnancy and Lactation

Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.

Side Effects and Adverse Reactions

Clinical research has reported increased liver enzymes, fatigue and hypercalcaemia in some participants. Findings from selected cancer populations do not establish the safety of a 25 mg tablet for other users. A dependable frequency category cannot be assigned to all potential reactions.

Overdose Protocol

For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.

Scientific & Technical Data

Pharmacodynamics

Enobosarm is a nonsteroidal androgen-receptor modulator. Receptor activation can affect androgen-responsive tissues and hormonal feedback; the desired tissue selectivity is not proof of clinical safety.

Pharmacokinetics

Human studies describe exposure under particular trial conditions. Their results do not demonstrate bioequivalence for a different tablet preparation. A dosing interval should not be inferred solely from a reported half-life.

Storage and Handling

Keep tablets sealed in the original container, protected from excessive heat, moisture and accidental access. Use storage and expiry conditions supported by the finished preparation's stability information. A laboratory compound's storage temperature does not establish appropriate medicinal tablet storage. Arrange disposal through a pharmacy or supervising research service.

Product request

Enquire about Ostarine (MK 2866)

Send a pricing, sample or distribution request. The product (Ostarine (MK 2866) (25 mg/tab · 100 tabs)) is included automatically, and our team replies within one business day.